Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9640908 | 0.86 | TSHR (0.62) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL10569888 | 0.86 | TSHR (0.68) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL10569117 | 0.84 | TSHR (0.71) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL16582531 | 0.84 | TSHR (0.71) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL16582463 | 0.84 | TSHR (0.71) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL8575705 | 0.83 | TSHR (0.59) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL1004267 | 0.81 | LOXL2 (0.64) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL17857810 | 0.80 | TSHR (0.72) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL4949211 | 0.78 | LOXL2 (0.61) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 | |
| SCHEMBL80140 | 0.78 | TSHR (0.55) | TSHRHSD17B10LOXL2CYP2A6KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572209-A4 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20060178370-A1 | Ketopiperazine derivatives as bradykinin antagonists | MERCK & CO., INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1572209-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Merck & Co., Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6908921-B2 | Quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004083173-A2 | KETOPIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004054584-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO., INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | TSHR 3915/4885HSD17B10 3384/4885LOXL2 1436/4885 |
| US-20060178370-A1 | Ketopiperazine derivatives as bradykinin antagonists | BDKRB1, BDKRB2, KLKB1 | TSHR 3010/4885HSD17B10 2374/4885LOXL2 1806/4885 |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | BDKRB1, BDKRB2, LTB4R2 | TSHR 3950/4885HSD17B10 2948/4885LOXL2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.